The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.08 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.16 — no flag raisedOK
- Earnings quality 84/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Kiniksa Pharmaceuticals International, plc reports it. History and quarterly detail are in the app.
- Product$677.6M
Leadership changes
From Kiniksa Pharmaceuticals International, plc's own filings, the day they're filed.
- Eben Tessari · Chief Strategy Officer · departureeff. 2026-04-30
- Ross Moat · Chief Operating Officer · appointmenteff. 2026-01-10
- Eben Tessari · Chief Strategy Officer · appointmenteff. 2026-01-10
Latest filings
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-05-29
- 8-K · Company announcement2026-05-26
- 8-K · Company announcement2026-05-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Kiniksa Pharmaceuticals International, plc, every answer cited to the official filings🔒
- The Intelligence Brief — added when Kiniksa Pharmaceuticals International, plc's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.